Navigation Links
Lentigen Receives U.S. Orphan Drug Designation for Novel Gene Therapy for glioblastoma multiforme
Date:2/13/2013

GAITHERSBURG, Md., Feb. 13, 2013 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells (product name: LG631-CD34) for bone marrow protection in the treatment of glioblastoma multiforme. Orphan drug designation qualifies Lentigen for seven years of market exclusivity following marketing approval by the FDA and provides other development-related incentives.

"We are very pleased that the FDA has granted our brain cancer product orphan drug status," said Tim Ravenscroft CEO of Lentigen Corporation. "The market exclusivity which this designation provides, together with our intellectual property rights, gives us increased impetus to advance the development of this product, enabling us to play our part in improving the lives of patients with glioblastoma."

"LG631-CD34 consists of the patients' adult hematopoietic stem cells genetically modified with a Lentiviral vector expressing a human MGMT gene variant, which is designed to protect the cells from the toxic side-effects of Temodar*, a standard of care treatment for glioblastoma multiforme" said Dr. Boro Dropulic , the Chief Scientific Officer of Lentigen Corporation. "Protection of blood-forming hematopoietic stem cells from the side-effects effects of Temodar would provide immediate benefits to patients. It  potentially enables higher doses and more intensive drug treatment with reduced toxicity, resulting in improved clinical outcomes.

LG631-CD34 is currently being evaluated in a NIH grant-funded Phase I clinical trial (http://www.clinicaltrials.gov/ct2/show/NCT01269424) at University Hospitals (
'/>"/>

SOURCE Lentigen Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
2. Immunotech Laboratories Receives $2M Funding Approval To Begin European Clinical Trials Testing For Companys Patented "IPF" HIV-AIDS Medicines
3. Unigene Receives 2013 Drug Delivery Partnerships Industry Achievement Award
4. iBio, Inc. Receives Approval from NYSE MKT of Compliance Plan
5. Physicians Capital Investments Receives "Outstanding Development Award" for Sandy, Oregon Project
6. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
7. Remique (TM), a Revolutionary Dietary Supplement, Manufactured in FDA Registered Facilities, Receives Raves from Compromised Immune System Sufferers
8. Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Sanger Sequencing Platform and HLA Typing Kits
9. Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
10. Morphotek Inc. Pilot Plant Receives 2013 Facility of the Year Award
11. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... is evident from the industry players that as a whole ... to the lack of promotional activities to make consumers aware ... acids. Among omega-3 ingredient sources algal oil is expected to ... vegetarian population in India . ... in growth stage of its lifecycle. Omega-3 fatty acids have ...
(Date:9/30/2014)... CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced the initiation of a ... to topotecan in subjects with extensive-stage small cell ... refractory to prior chemotherapy. Aldoxorubicin is CytRx,s modified ... has received Orphan Drug Designation for the treatment ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
Breaking Medicine Technology:Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... HealthCare presented results from a global Phase II study ... detection of cerebral beta-Amyloid plaques, at the 19th World ... of the Phase II study was to investigate the ... clinical diagnosis of probable Alzheimer,s disease and Healthy Volunteers ...
... ADA,s 2009 Convention -- When Shawnae Jebbia won the ... a fairytale career. She appeared at events throughout the world, ... But Shawnae,s world unexpectedly changed when she was diagnosed with ... adventure, she had a difficult time understanding and accepting the ...
Cached Medicine Technology:Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 3Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3
(Date:9/30/2014)... For millions of overweight Americans, regular exercise remains a ... type 2 diabetes. However, a new study suggests ... for others, depending on their genes. "While physical ... as effective for everyone when it comes to preventing ... Ruth Loos, director of the Genetics of Obesity and ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
(Date:9/30/2014)... AxoGen, Inc. (NASDAQ: AXGN), a leading ... market, announced the presentation of clinical data for Avance® ... of the Hand (ASSH) 2014 Annual Meeting which took ... The ASSH Best Paper Award was given to ”Functional ... Large Gap Nerve Discontinuities: Outcomes From a National Registry ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 During ... on natural approaches to health including achieving hormonal ... nutrient deficiencies and detoxification. , ... follows: , Date: October 6-9, 2014, Location: Online ... register: http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, ...
(Date:9/30/2014)... Washington, DC (PRWEB) September 30, 2014 ... private insurance exchanges within three years, profoundly impacting health ... pleased to announce its upcoming virtual conference, “Private ... offer a valuable lesson on where private health insurance ... the industry is expected to look like when they ...
Breaking Medicine News(10 mins):Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:New Atlantic Information Services Virtual Conference Will Detail Private Exchange Strategies for Health Plans 2
... to face depression, says a study that suggests that such ... substantial illness with significant morbidity for patients and their families ... the health portal WebMd. , ,Lee S. Cohen ... Boston women aged 36 to 45 for up to six ...
... study in the April edition Journal of the American ... boost the number of children// who select a calcium-rich ... the amount of saturated fat consumed from calcium-rich beverages. ... three ethnically diverse elementary schools in Florida. The results ...
... Children who drink juice do not face the risk of ... of the juice in children’s diet and body mass index ... this conclusion. // ,According to foodconsumer.org, he ... mass index for their age and that children aged 12-18 ...
... in Hypertension: Journal of the American Heart Association sleeping ... may increase risks of high blood pressure. // Columbia ... of Physicians and Surgeons conducted the study. ... at Columbia University's Mailman School of Public Health reported ...
... people were being failed by the NHS says a joint ... Commission for Social Care Inspection. // Elder abuse is hurting ... people are subject to patronising and thoughtless attitudes from some ... place to another, their meals are whisked away uneaten for ...
... men who were born with an "incurable" genetic disorder ... infections has been repaired with Gene therapy. // Sixteen ... the once severely ill patients show signs of complete ... that this latest success will lead to further operations ...
Cached Medicine News:Health News:Neglect of the Elderly by the Community 2Health News:Gene Therapy Helps To Cure 'Incurable' Illness 2
... Model V-1000 is a new addition to the ... This high performance pump can achieve an ultimate ... of 64 L/min. Applications For ... concentrators Distillation applications from lab size ...
... deliver critical performance for all vacuum requirements. ... pump performance to suit all applications. The ... checking of proper oil levels at a ... designed to work with all Thermo Savant ...
... The OFP400 Oil-free Vacuum Pump is designed for ... high chemical resistance, quiet running and eliminates oil ... any oil to operate. Less mess, less fuss., ... 4-headed design with chemically resistant solid ETFE and ...
... several different two-stage, oil-sealed, rotary vane vacuum ... applications. Each pump comes complete with a ... and Oil Mist Filter (EMF-10). The GBORK ... ballast to keep the oil clean without ...
Medicine Products: